Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,695 questions · 4,979 findings · 433 reviews

No studies found 998 · 20%GRADE not reported 1,140 · 22.9%Very low 1,024 · 20.6%Low 1,029 · 20.7%Moderate 636 · 12.8%High 152 · 3.1%

Clotrimazole 50 mg (partially absorbed) vs Clotrimazole 10 mg (partially absorbed)

Clinical: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Clotrimazole 50 mg (partially absorbed) showed no clear difference in clinical: eradication of oral candidiasis compared with clotrimazole 10 mg (partially absorbed); GRADE not reported.

1 finding from 1 review

Fluconazole (absorbed from GI tract) vs Ketoconazole (absorbed from GI tract)

Clinical: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Fluconazole (absorbed from GI tract) showed no clear difference in clinical: eradication of oral candidiasis compared with ketoconazole (absorbed from GI tract); GRADE not reported.

1 finding from 1 review

Clotrimazole 50 mg (partially absorbed) vs Clotrimazole 10 mg (partially absorbed)

Mycological: eradication of oral candidiasis · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis

Clotrimazole 50 mg (partially absorbed) led to higher mycological: eradication of oral candidiasis compared with clotrimazole 10 mg (partially absorbed); GRADE not reported.

1 finding from 1 review

Intermittent oral vs oral calcitriol

Fall in PTH · patients with bone disease in children with chronic kidney disease

Intermittent oral showed no clear difference in fall in PTH compared with daily oral calcitriol (moderate certainty).

2 findings from 1 review

Oral iron sulphate vs oral iron hydroxide polymaltose complex

Serious adverse events ‐ active or inactive disease (14 days) · IBD patients

It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).

1 finding from 1 review